We purchased dorsomorphin (Compound C, 6-[4-(2-piperidin-1-yl-ethoxy)phenyl]-3-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine) from EMD Biosciences. We synthesized LDN-193189 (4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline) as previously described6 (link), determined its purity (99.8%) by HPLC and confirmed its structure by 1H-NMR and high-resolution mass spectrometry. The vehicle was 2% (wt/vol) (2-hydroxypropyl)-β-cyclodextrin in PBS, pH 7.4. We purchased dexamethasone from Sigma. Recombinant human BMP4, platelet-derived growth factor-BB and TGF-β were obtained from R&D Systems. We produced adenoviruses expressing GFP and Cre and quantified them by the plaque-titer method.
Protocol detail
Synthesis and Validation of LDN-193189
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
1h nmr
Adenoviruses
Bmp4
Cyclodextrin
Dexamethasone
Dorsomorphin
Hplc
Human
Hydroxypropyl
Ldn 193189
Mass spectrometry
Piperazin
Plaque
Platelet derived growth factor bb
Pyrimidine
Quinoline
Tgf β
Corresponding Organization :
Other organizations : Harvard University, Vanderbilt University, Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Saitama Medical University, National Institutes of Health, University of Michigan–Ann Arbor
Top 5 similar protocols
Protocol cited in 9 other protocols
Variable analysis
independent variables
- Dorsomorphin (Compound C, 6-[4-(2-piperidin-1-yl-ethoxy)phenyl]-3-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine)
- LDN-193189 (4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline)
- Dexamethasone
- Purity of LDN-193189 (99.8%) determined by HPLC
- Structure of LDN-193189 confirmed by 1H-NMR and high-resolution mass spectrometry
- Vehicle (2% (wt/vol) (2-hydroxypropyl)-β-cyclodextrin in PBS, pH 7.4)
- Recombinant human BMP4, platelet-derived growth factor-BB and TGF-β obtained from R&D Systems
- Adenoviruses expressing GFP and Cre quantified by the plaque-titer method
- Positive control: not specified
- Negative control: not specified
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!